Early studies of national data suggest that the Share 35 allocation policy increased liver transplants without compromising posttransplant outcomes. Changes in center-specific volumes and practice patterns in response to the national policy change are not well characterized. Understanding center-level responses to Share 35 is crucial for optimizing the policy and constructing effective future policy revisions. Data from the United Network for Organ Sharing were analyzed to compare center-level volumes of allocation-Model for End-Stage Liver Disease (aMELD) 35 transplants before and after policy implementation. There was significant center-level variation in the number and proportion of aMELD 35 transplants performed from the pre-to post-Share 35 period; 8 centers accounted for 33.7% of the total national increase in aMELD 35 transplants performed in the 2. (1,2) The Share 35 policy resulted from a desire to decrease waitlist mortality by improving access to deceased donor livers for the sickest patients.
Share 35 policy resulted from a desire to decrease waitlist mortality by improving access to deceased donor livers for the sickest patients. (3) (4) (5) (6) (7) To achieve this goal, donor livers are offered to a merged list of regional candidates with MELD 35 before they are offered to other local and then regional candidates with MELD < 35. Preimplementation prediction models suggested that sharing at a MELD cutoff of 35 would result in a reduction in total wait-list mortality with minimal increases in travel distances and cold ischemia time, but the policy change and its subsequent impact remain controversial. (8) In comparing the early national experience in the year before and the year after Share 35 implementation, Massie et al. (9) reported a decreased discard rate and decreased wait-list mortality with the new policy. These effects were seen in the absence of significant changes in the number of patients listed at MELD 35, cold ischemia time, or early (5-month) posttransplant mortality. These early results suggest that Share 35 achieved its goals with minimal downside.
Share 35 is a national policy, but implementation occurs at a regional level. Consequently, effects may be different across regions and between individual transplant centers-Halazun et al. recently identified regional variation in post-Share 35 outcomes. (10) Center-level practices toward transplanting allocation-Model for End-Stage Liver Disease (aMELD) 35 patients depend on both center-level decisions and the regional environment. Aggregated national data, therefore, may not capture the significance of local effects.
At present, the impacts of Share 35 on individual transplant centers are not well characterized. Several important questions remain. First, did the new policy yield broad and homogeneous effects, or did significant pockets of local center-level effects account for what was observed at the aggregated national level? Second, did the policy change correlate with any identifiable center-level behavioral changes, such as alterations in transplant volume, recipient listing practices, or organ acceptance patterns? Third, what was the actual calculated laboratory MELD score at the time of transplant for the patients who were listed with an aMELD 35 and potentially received regionally shared donor livers?
Patients and Methods

DATA SOURCE
We used a Standard Transplant Analysis and Research file from the United Network for Organ Sharing/ Organ Procurement and Transplantation Network as the data source for the study. This file included data on all liver transplant recipients with encrypted codes for transplant center and donor service area. Match run data were not required to complete any of the analyses. The University of Pennsylvania institutional review board (IRB) deemed the research IRB review exempt as authorized by 45 CFR 46.101, category 2.
STUDY POPULATIONS
Adult (age 18 years) patients who received a deceased donor liver transplant between December 18, 2010 and December 17, 2015 were included in the study. Patients allocated as status 1 were included in the analysis, except when otherwise stated. Recipients of simultaneous liver-kidney transplants were also included because it was anticipated that Share 35 would increase simultaneous liver-kidney transplant volume, but recipients of other multivisceral transplants were excluded from the analysis. The transplants included for analysis do not all specifically represent regionally shared organs.
Recipients were divided into 4 equivalent 15-month "eras" by date of transplantation: For most analyses, recipients from era 1 and era 2 were combined to form the 2.5-year "pre-Share 35 period" and those from era 3 and era 4 the 2.5-year "post-Share 35 period."
MELD SCORES
The aMELD is the MELD score for each recipient that was used on the match run that yielded the transplanted organ. Because patients with aMELD 35 can carry that aMELD score for up to 7 days, we defined the calculated time-of-transplant (TOT) laboratory MELD as a recipient's MELD calculated from laboratories provided in the Standard Transplant Analysis and Research file that were obtained before The content is the responsibility of the authors alone and does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US government. The data reported here have been supplied by the United Network for Organ Sharing as the contractor for the Organ Procurement and Transplantation Network. The interpretation and reporting of these data are the responsibility of the author(s) and in no way should be seen as an official policy of or interpretation by the Organ Procurement and Transplantation Network or the US government.
Additional supporting information may be found in the online version of this article. 
TOT Laboratory MELD Scores and Pretransplant Patient Locations
Given the ability for patients with aMELD 35 to hold their aMELDs for up to 7 days and remain eligible for regionally shared donor organs regardless of potential improvements in clinical status, we characterized the TOT laboratory MELD scores for patients transplanted with aMELD 35 pre-and post-Share 35. Similarly, we characterized the pretransplant location for patients transplanted with aMELD 35 preand post-Share 35. Status 1 patients were excluded from this analysis because they categorically precede typical listed patients in allocation, and the change in MELD score is not meaningful in organ allocation to patients with fulminant hepatic failure or early hepatic artery thrombosis.
Transplant Proportions (by MELD Group)
MELD groups were created in order to investigate the change in relative transplant volumes by MELD group for patients transplanted with aMELD 35 pre-versus post-Share 35. MELD groups were defined as follows: There was concern that some patients may have a calculated MELD that was competitive with an exception MELD score and that this would make categorization more challenging. When this was specifically assessed, only 14 of 526 (2.7%) aMELD 35 exception cases had a TOT laboratory MELD score within 5 points of their aMELD. Concern about confounding between groups seems unwarranted.
Statistical Analysis
Statistical analyses were performed with STATA SE for MAC OS X, version 14.0 (StataCorp LP, College Station, TX) using Pearson's chi-square test. Pearson correlation coefficients were used to measure linear dependence between various changes in transplant volumes and new wait-listings as detailed above.
Results
REGION-LEVEL VARIATION IN TRANSPLANT VOLUME
The percentage of deceased donor transplant recipients who had an aMELD 35 increased from 19.5% (n 5 1358) and 18.7% (n 5 1287) in era 1 and era 2, respectively, to 27.9% (n 5 2019) and 26.8% (n 5 2072) in era 3 and era 4, respectively (P < 0.001).
There was an increase in the number of aMELD 35 transplants performed in all 11 regions from pre-to post-Share 35, but there was also substantial regionto-region variation in the magnitude of these changes (Supporting Fig. 1 ). Because region 9 had regional sharing prior to Share 35 implementation, we did not expect to see a significant impact of the policy in this region but included it for completeness. There was no evidence of a bolus effect in the postShare 35 period; regional volumes of aMELD 35 transplants were comparable between era 3 and era 4 following Share 35 implementation (Supporting Table 1 ). The percent of aMELD 35 transplants that were simultaneous liver-kidney transplants did not change appreciably from 13.8% and 15.2% in era 1 and era 2, respectively, to 14.1% and 15.3% in era 3 and era 4, respectively (P 5 0.54).
CENTER-LEVEL VARIATION IN TRANSPLANT VOLUME AND LISTING PRACTICES
The total number of aMELD 35 transplants increased by 1446 from the 2. (Fig. 1) . These increases were disproportionate to these centers' total transplant volume: the 25 centers performed 32.1% of all pre-Share 35 liver transplants, whereas the 8 centers performed 10.2%.
The increase in aMELD 35 transplants from pre-to post-Share 35 that was observed at each of the 8 centers exceed any era-to-era variation in volume seen at these centers (Fig. 2) . The 8 centers that had the largest increase in aMELD 35 transplants represented 5 regions, whereas the 25 centers that demonstrated an increase of 20 aMELD 35 transplants in the post-Share 35 period came from 9 different regions. No more than 5 of the 25 centers came from any 1 region (Supporting Fig. 2) . 
TOT LABORATORY MELD SCORES
The aMELD 35 scores are valid for 7 days. Although centers generally attempt to capture rising rather than falling MELD scores with recertification, TOT laboratory MELD can be increased or decreased relative to a patient's aMELD (Supporting Fig. 3 ). In 7 of 11 regions, the percentage of transplant recipients who were allocated a liver with aMELD 35 and maintained a TOT laboratory MELD 35 decreased in the 2.5-year period after the policy change (Fig. 5) . Nationally, out of all of the patients transplanted with aMELD 35, the percentage of those who had a TOT laboratory MELD 35 decreased slightly from 71.2% pre-Share 35 to 69.6% post-Share 35 (P 5 0.15).
In 
PRETRANSPLANT PATIENT LOCATIONS
Nationally, there was a small increase in the percentage of aMELD 35 transplant recipients in the intensive care unit from pre-to post-Share 35 (38.8% to 43.5%), and this reflected a decrease in the percentage of aMELD 35 transplant recipients in the nonintensive care unit inpatient setting (47.5% to 42.1%). The percent of aMELD 35 transplant recipients who came from home for their transplant increased slightly from pre-to post-Share 35 (13.8% to 14.5%).
TRANSPLANT PROPORTIONS (BY MELD GROUP)
The 
CHANGES IN DONOR RISK INDEX
To evaluate whether the increase in aMELD 35 transplants performed in the post-Share 35 period was accompanied by decreases in donor organ quality for these recipients, centers were divided into 4 quartiles based on their absolute increase in aMELD 35 transplants performed from the pre-to post-Share 35 periods. For each quartile of centers, the median donor risk index (DRI) was compared pre-versus post-Share 35. The median DRI for donor livers used for all transplant recipients and for donor livers used for only aMELD 35 recipients were nearly identical between quartiles and unchanged from pre-to post-Share 35 (Supporting Table 2 ). 
ETIOLOGY
The etiology of liver disease was tabulated, by recipient age, for all aMELD 35 recipients in the pre-and post-Share 35 periods (Table 1 ). There was a 9.2% increase from pre-to post-Share 35 in transplants for alcohol-induced liver disease in patients ages 18-39 years and an 8.4% increase in patients ages 40-59 years. The next largest increase for any etiology or age group was a 3.2% increase in transplants for recipients age 60 years with hepatitis C virus (HCV).
Discussion
Share 35 liver allocation policy aimed to increase access to donor livers for the sickest patients across the nation. National data suggest that the policy achieved this goal in aggregate, (9) but analysis of 2.5 years of post-policy implementation data reveals that a minority of centers were responsible for most of the increased volume of high-MELD transplants. Many centers saw minimal change in volume of aMELD 35 transplants after Share 35, whereas the increases in aMELD 35 transplants seen in the post-Share 35 period were fairly concentrated, with under one-quarter (25/ 110, 22.7%) of centers accounting for nearly twothirds (65.0%) of the national increase in aMELD 35 transplants. A similar phenomenon of center-level concentration was reported with nationally placed livers. (11) Given the distribution of regions represented by these centers, the disparate local effects are not explained by regional differences in median aMELD.
The increase in aMELD 35 transplants was not solely attributable to centers that did the most high-MELD transplants, such as centers in region 5 where the median-MELD is near 35, or to centers with the 
These increases coincided with a report by Mathurin et al. on the success of liver transplantation in patients with acute alcoholic hepatitis. (13) Preimplementation simulations used to assess the expected impact of policy change may fail to predict the changes in human behavior that accompany policy change-such as the surge in transplantation of patients with acute alcoholic hepatitis seen after Share 35 implementation. These data join a nascent body of literature highlighting the significant variation in transplant center practices and organ offer acceptances for the sickest patients and are consistent with prior reports of centers changing practice patterns in response to allocation changes. (14, 15) In light of these shortcomings, Schnier et al. have advocated for greater synergy between transplant surgeons and economists, who possess greater expertise in human behavior and decision making under risk and may be better equipped to counsel policy makers in making allocation policy changes. (16) In addition to alterations in listing practices, changes in competitive environment, center personnel, organ acceptance patterns, and regional access to higher-performing organ procurement organizations may influence a center's increase in aMELD 35 transplant volume. We did not identify changes in the donor liver quality, or DRI, used for aMELD 35 transplants pre-compared with post-Share 35, (17) suggesting that the centers which demonstrated a large increase in volume of aMELD 35 transplants did not do so on the basis of changes in organ acceptance practices. A recent study by Washburn et al. found that centers are actually less likely to accept organs for aMELD 35 patients after the policy change. (18) Goldberg et al. similarly reported a significant decline in liver acceptance offers after implementation of Share 35 as well as varied and significant changes in organ offer acceptance rates at the center level pre-versus post-Share 35. (19) Together, these studies provide further clarification that alterations in organ acceptance practices did not drive center-level increases in aMELD 35 transplant volume.
Listed patients with HCC exception scores previously had more favorable access to transplantation compared with nontumor patients, (20) and Share 35 was expected to mitigate this difference. We report preservation of the transplant rates for the cohort of patients with MELD < 35 at allocation by exception. Most of the increase in transplant rates for patients with calculated MELD 35 at allocation was balanced by a decrease in transplant rates for patients with nonexception score calculated MELD < 35 at allocation, whereas the remaining increase can be attributed to the increased total number (n 5 1138) of deceased donor liver transplants performed in the post-Share 35 period. This finding was true across all regions and suggests that regional sharing patterns typically involve regional utilization of a liver for a decompensated patient with aMELD 35, rather than for a local decompensated patient with a calculated laboratory MELD < 35. It will be important to understand whether these regional allocations result in livers being distributed to patients with significant differences in MELD; a difference of a small number of MELD points may not have prognostic value in outcome. (21, 22) Over 30% of patients transplanted with aMELD 35 did not maintain a TOT laboratory MELD 35, yet patients with aMELD 35 by HCC exception accounted for only 2.6% of the aMELD 35 transplants performed post-Share 35. It is therefore unlikely that the recently enacted HCC exception score cap of 34 will significantly affect the findings reported in this study. (23) Given the proportion of patients who had a MELD score that improved in the time between listing laboratory and TOT laboratory values, as well as the 14.5% of aMELD 35 recipients who came from home for their transplant, the ability to capture and hold an aMELD of 35 for 7 days regardless of changes in clinical status may need to be reconsidered in light of regional or proposed national sharing. More frequent updating of aMELD scores could lead to greater transparency with respect to true patient disease and risk of wait-list mortality and improve an allocation system that focuses on transplanting the sickest first. The importance of this is underscored by the finding by Chow et al. that top local candidates who lose priority for a donor liver to a regional candidate with aMELD 35 have a 15% chance of dying on or being removed from the waiting list in the ensuing 12 months. (21) It is important to note the limitations of this study. There is variability in the quality of data associated with United Network for Organ Sharing registries that were previously characterized by Massie at al. (24) We cannot be certain that the effects observed were caused by Share 35 policy implementation or that linkages between listing and volume are truly causal. Although we identified an increase in transplant rates of patients with an aMELD of 35 who were HCC exception cases post-Share 35, we did not evaluate if the profile of donor risk used in these recipients changed after policy implementation. Last, it is difficult to make durable conclusions from a study of only 2.5 years of post-policy implementation data. To fully judge the value of this policy, data on wait-list and posttransplant outcomes from a longer-term period than that what is currently available will need to be considered.
The report by Massie et al. on the 1-year patient outcomes after Share 35 policy implementation was promising, (9) but other recent studies have illuminated caveats. Annamalai et al. failed to identify significant change in wait-list mortality nationally. (25) Halazun et al. raised concern about the "one size fits all" nature of Share 35 given the regional variation that they observed in their analysis of post-Share 35 outcomes. (10) Perhaps most important, longterm outcomes after Share 35 will not available for several more years. (26, 27) In conclusion, Share 35 represents a first step toward increasing access to liver transplantation for the sickest patients. As data on the impact of Share 35 matures, the liver transplant community will benefit from ongoing analysis and optimization of sharing policies, especially those that balance the competing interests of preservation of outcomes and cost with maximizing organ utility, reducing wait-list mortality, and minimizing center and regional disparities in access. (22, 28) Center-level effects are harder to study than national effects, but because patients are transplanted at centers, center-level effects are determinative of patients' experiences with policy change. An understanding of the center-level changes that occur with policy implementation must be considered carefully at the time of policy debate and studied afterward to assure that such changes translate into the desired outcomes. (29) 
